NCT06048887View on ClinicalTrials.gov

Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

April 11, 2022

Study Completion Date

April 11, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

CRN04894 Oral Solution

CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.

DRUG

Placebo Oral Solution

Placebo

Trial Locations (1)

33143

QPS-Miami Research Associates, Miami

Sponsors
All Listed Sponsors
lead

Crinetics Pharmaceuticals Inc.

INDUSTRY